ATE386106T1 - Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung - Google Patents

Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung

Info

Publication number
ATE386106T1
ATE386106T1 AT96919200T AT96919200T ATE386106T1 AT E386106 T1 ATE386106 T1 AT E386106T1 AT 96919200 T AT96919200 T AT 96919200T AT 96919200 T AT96919200 T AT 96919200T AT E386106 T1 ATE386106 T1 AT E386106T1
Authority
AT
Austria
Prior art keywords
viruses
recombinant viruses
compositions
cytomegalovirus
recombinant
Prior art date
Application number
AT96919200T
Other languages
English (en)
Inventor
Enzo Paoletti
Steven Pincus
William Cox
Elizabeth Kauffman
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Application granted granted Critical
Publication of ATE386106T1 publication Critical patent/ATE386106T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96919200T 1995-06-06 1996-06-06 Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung ATE386106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47101495A 1995-06-06 1995-06-06
US08/658,665 US5997878A (en) 1991-03-07 1996-06-05 Recombinant poxvirus-cytomegalovirus, compositions and uses

Publications (1)

Publication Number Publication Date
ATE386106T1 true ATE386106T1 (de) 2008-03-15

Family

ID=27043299

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919200T ATE386106T1 (de) 1995-06-06 1996-06-06 Rekombinante poxvirus-cytomegalovirus zusammensetzungen und ihre verwendung

Country Status (7)

Country Link
US (1) US5997878A (de)
EP (2) EP1925662A1 (de)
JP (1) JP3940959B2 (de)
AT (1) ATE386106T1 (de)
AU (1) AU722867B2 (de)
CA (1) CA2223282A1 (de)
WO (1) WO1996039491A1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US7374768B1 (en) 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
ATE181108T1 (de) 1991-08-26 1999-06-15 Immuno Ag Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus
ES2243937T3 (es) * 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
FR2757169B1 (fr) * 1996-12-13 1999-03-05 Inst Nat Sante Rech Med Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
WO2000073476A1 (en) * 1999-05-28 2000-12-07 Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
EP2390352A1 (de) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systeme und Methoden zur Erhöhung der Milchproduktion bei Tieren
SI1620456T1 (sl) 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
CA2556911C (en) 2004-02-19 2013-07-30 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
WO2006017724A1 (en) * 2004-08-06 2006-02-16 Becton, Dickinson And Company Sequences and methods for detection of cytomegalovirus
ES2343270T3 (es) 2005-04-25 2010-07-27 Merial Ltd. Vacunas contra el virus nipah.
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (de) 2005-11-14 2017-11-01 Merial, Inc. Gentherapie bei nierenversagen
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080138354A1 (en) * 2006-07-21 2008-06-12 City Of Hope Cytomegalovirus vaccine
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
PE20141398A1 (es) 2008-07-16 2014-10-18 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
US8871220B2 (en) 2009-04-03 2014-10-28 Merial Limited Newcastle disease virus vectored avian vaccines
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
US8986706B2 (en) 2010-08-31 2015-03-24 Merial, Inc. Newcastle disease virus vectored herpesvirus vaccines
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
DK3205353T3 (da) 2011-03-21 2021-04-06 Altimmune Inc Hurtig- og langtidsvirkende immunologisk terapeutisk middel
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20140296248A1 (en) 2011-04-04 2014-10-02 Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
JP6407714B2 (ja) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
ES2674439T3 (es) 2011-06-01 2018-06-29 Merial, Inc. Administración sin aguja de vacunas contra el VSRRP
CA2844927C (en) 2011-08-12 2017-10-31 Merial Limited Vacuum-assisted preservation of biological products, in particular of vaccines
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
EP2958586B1 (de) 2013-02-21 2018-09-05 Boehringer Ingelheim Vetmedica GmbH H5-proteine aus dem h5n1-influenzavirus zur verwendung als arzneimittel
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
CA2943816A1 (en) 2014-04-03 2015-10-08 Boehringer Ingelheim Vetmedica, Inc. Porcine epidemic diarrhea virus vaccine
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
PH12017502380B1 (en) 2015-06-23 2022-10-26 Merial Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
EP3344289B1 (de) 2015-08-31 2020-01-29 Boehringer Ingelheim Vetmedica GmbH Pestivirusimpfstoffe gegen kongenitalen tremor
US20170072042A1 (en) 2015-09-16 2017-03-16 Boehringer Ingelheim Vetmedica, Inc. Salmonella choleraesuis-salmonella typhimurium vaccines
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
UY37408A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Vacuna de vectores contra el virus de la gripe “a” porcina
MX2019003161A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion orf70 de ehv.
MX391049B (es) 2016-09-20 2025-03-21 Boehringer Ingelheim Vetmedica Gmbh Nuevos promotores
ES2956050T3 (es) 2016-09-20 2023-12-12 Boehringer Ingelheim Vetmedica Gmbh Vectores de adenovirus caninos
UA130511C2 (uk) 2016-11-03 2026-03-11 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу й вірусу свинячого репродуктивного й респіраторного синдрому та спосіб її одержання
EP4570264A3 (de) 2016-11-03 2026-01-21 Boehringer Ingelheim Vetmedica GmbH Impfstoff gegen schweineparvovirus
WO2018140766A2 (en) 2017-01-30 2018-08-02 Boehringer Ingelheim Vetmedica, Inc. Porcine coronavirus vaccines
JP7083362B2 (ja) 2017-07-12 2022-06-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド セネカウイルスａ免疫原性組成物およびその方法
MX2020003071A (es) 2017-09-23 2020-07-28 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresion de paramyxoviridae.
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
US11033616B2 (en) 2018-02-23 2021-06-15 Boehringer Ingelheim Vetmedica Gmbh Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
JP7245260B2 (ja) 2018-03-19 2023-03-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｅｈｖ挿入部位ｕｌ４３
CA3091954A1 (en) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh New ehv with inactivated ul18 and/or ul8
CN119488586A (zh) 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
US11464852B2 (en) 2018-09-20 2022-10-11 Boehringer Ingelheim Vetmedica Gmbh Modified PEDV spike protein
EP3852800A1 (de) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasaler vektorimpfstoff gegen epidemische virusdiarrhoe
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2021158878A1 (en) 2020-02-06 2021-08-12 Boehringer Ingelheim Animal Health USA Inc. Polypeptides useful for detecting anti-rhabdovirus antibodies
TWI871709B (zh) 2020-06-21 2025-02-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CN116438202A (zh) 2020-10-05 2023-07-14 勃林格殷格翰动物保健美国有限公司 包含圆环病毒科衣壳蛋白的融合蛋白及其构成的嵌合病毒样颗粒
WO2022076979A1 (en) 2020-10-05 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
JP2025511739A (ja) 2022-04-05 2025-04-16 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ロタウイルスに対するワクチン接種のために有用な免疫原性組成物
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
CA1335429C (en) * 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
EP0436537A4 (en) * 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
EP0575491B1 (de) * 1991-03-07 2003-08-13 Virogenetics Corporation Gentechnologisch hergestellter stamm für impfstoffe
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
WO1994023744A1 (en) * 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine

Also Published As

Publication number Publication date
US5997878A (en) 1999-12-07
EP0837928B1 (de) 2008-02-13
EP0837928A1 (de) 1998-04-29
CA2223282A1 (en) 1996-12-12
EP1925662A1 (de) 2008-05-28
WO1996039491A1 (en) 1996-12-12
AU6160196A (en) 1996-12-24
JP2001520507A (ja) 2001-10-30
AU722867B2 (en) 2000-08-10
EP0837928A4 (de) 2003-01-22
JP3940959B2 (ja) 2007-07-04

Similar Documents

Publication Publication Date Title
EP0837928A4 (de) Zusammensetzungen aus rekombinierten poxvirus-cytomegalovirus und ihre verwendung
ATE395932T1 (de) Rekombinanter immunschwächepoxvirus
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
DE69636487D1 (de) Zusammensetzungen zur Immuntherapie und Diagnose von Tuberculosis
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
DE69941059D1 (de) Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
BR9807873A (pt) Vacinas de flavivìrus quiméricos
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
WO2001032711A3 (en) Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
PL368049A1 (en) Diagnostic assays for parvovirus b19
ATE404219T1 (de) Rekombinante poxvirus-calicivirus zusammensetzungen und anwendungen
ES2187424T3 (es) Sistema catalizador, procedimiento y composiciones de silicona.
WO1995003414A3 (en) Chicken anemia virus mutants and vaccines and uses based on the viral proteins vp1, vp2 and vp3 or sequences of that virus coding therefor
DE69627526D1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
DE59712852D1 (de) Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
ATE358716T1 (de) Polypeptide zur auslösung einer immunreaktion gegen krebs
EP0990703A4 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
EP1840209A3 (de) Adeno-assoziierten Virusvektoren und deren Verwendung.
DE69332375D1 (de) Hundecoronavirus s gen und verwendung davon
ATE310805T1 (de) Genmodifizierte yt zelllinie und ihre verwendung
DE69616288D1 (de) Nukleotid sequenzen und daraus abgleitete aminosäuresequenzen vom tumorgen int 6

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties